Latino Semaglutide Study

NCT05087342 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of semaglutide, a medication, on weight loss in adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 119 people

Who can join Ages 18–75 · all sexes

Timeline Started 2022-12 · est. completion 2024-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05087342 ↗

Description as written by the study sponsor.

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

Treatments tested

Semaglutide 2.4mg Drug

The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
Placebo Drug

A placebo will be given to the control group per the schedule outlined in the armed description.

Main thing measured	Assessment of weight loss.
Sponsor	Loma Linda University
Conditions studied	Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05087342 ↗